Early access to medicines scheme (EAMS) scientific opinion: Atezolizumab in combination with bevacizumab for the treatment of adult patients with unresectable hepatocellular carcinoma who have received no prior systemic therapy

This positive scientific opinion was based on a study (n=501) which showed the proportion of patients without progression of disease was 54.5% in the atezolizumab and bevacizumab group vs. 37.2% in those treated with sorafenib at 6-month follow-up.

Medicines and Healthcare products Regulatory Agency